Skyrocketing doxy price gouging shows further action needed
This article was originally published in Scrip
Doxycycline has been in such short supply in the US that prices for the broad-spectrum antibiotic, which is used to treat and prevent Lyme disease, malaria, acne, sexually transmitted diseases and other infections, have risen astronomically, from just a few dollars to many hundreds of dollars per treatment according to IMS figures and anecdotal reports.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.